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Introduction: Chest physiotherapy (CP) is used in cystic fibrosis (CF) even if there is no robust scientific evidence of a beneficial effect. We
investigated the effects of a training with a specific device (SpiroTiger®) in a group of CF patients. This device, developed for respiratory training
through maximal inspirations and espirations without hypocarbia, may improve respiratory function and mucus clearance. Patients where
instructed and trained by a physiotherapist with individualized settings of training parameters.
Methods: Twenty-four patients were enrolled in an open-label 1 year observational study. Baseline and post intervention measurements were
determined by lung function (FVC, FEV1, FEF 25-75), patients’ opinions on physiotherapy (questionnaires), need for antibiotic treatment (clinical
follow-up and records) and perception of physical fitness (questionnaires) in the year before and in the year of intervention. Adherence to
physiotherapy was monitored by means of a specific device software.
Results: Increased lung function (FEV1 pb0.01), perception of physical fitness (pb0.001) and a reduction in the need for intravenous antibiotic
treatment (pb0.001) were reported. Adherence to treatment was good/acceptable in 92% of patients.
Conclusions: This study shows an association between training through a specific device and improved lung function. Further trials are needed to
confirm this report.
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Chest physiotherapy (CP) is widely used in patients with CF
[1]. However, there is no strong evidence to support the
assumption that CP has a beneficial effect [2,3]. High pressure
positive expiratory pressure (HiPEP) mask therapy, carried out
with the AstraTech PEP mask system [4] is the most used
physiotherapy technique in our centre. There is no evidence that
positive expiratory pressure it is more or less effective than
other forms of physiotherapy [5].
Chronic obstructive lung disease causes hyperinflation with
alterations in chest structure and muscle function [6]. The loss of
fat-free mass has been associated with a reduction in skele-
tal muscle mass which reduces the inspiratory muscle function⁎ Corresponding author. Tel.: +39 0403785312; fax: +39 0403785452.
E-mail address: alessandro.amaddeo@gmail.com (A. Amaddeo).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2007.12.003[7–9]. There is considerable variability in published data
regarding respiratory muscles strength in CF. Some authors
report that strength is preserved or even increased, while others
report significant reduction [6,10]. In the latter hypothesis skeletal
muscle alterations and the interaction between the pattern of
thoracic adaptation and the function of respiratory muscles may
play a role in worsening the lung function and in hyperinflation
[6,8,9]. Therefore a physiotherapy targeted at improving
specifically chest function may also improve lung function [11].
Respiratory muscle training may also work by removing
secretions thus effectively lowering residual volume and functional
residual capacity levels, which allows the muscles to work
effectively onmore advantageous parts of the length tension curve.
We selected a specifically designed respiratory device
(SpiroTiger®, MVM, Bologna, Italy) that has been used with
athletes to train breathing muscles and improve pulmonary
function. One advantage of a respiratory device in comparisond by Elsevier B.V. All rights reserved.
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dependent on endurance of inferior limb muscles.
Our hypothesis was that the specific properties of the device
could not only provide respiratory muscles training but also
achieve an improvement of the whole lung function. Training
through this device may induce high flows by mean of maximal
inspirations with radial traction on airways and, at the same time,
avoid hypocarbia and dynamic hyperinflation. Increased air flow
could also mobilize secretions and improve mucus clearance.
We performed a prospective clinical trial in order to assess
the efficacy of respiratory training with SpiroTiger®. This is a
pilot study aimed at confirming the positive results obtained in
our Hospital in few subjects, in preparation for a multi-centre
controlled clinical trial.
2. Materials and methods
The study was conducted in one CF centre of a Tertiary
University Hospital (Institute of Child Health IRCCS Burlo
Garofolo, Trieste, Italy) between January 2004 and December
2006.
2.1. Selection of patients
All patients with the following characteristics were enrolled:
1) Former diagnosis of CF based on clinical criteria, pathologic
sweat test (Na and Cl levels N70 mmol/L) and CF genotype.Fig. 1. Spiro Tiger. Description: Held unit with specific valve and respiratory pouch. P
the breathing frequency and depth during training. The display provides instruction
frequency is paced by a moving light and brief sounds. In case of substantial deviatio
warnings. The data collected during a training session are passed by cable to the ba2) Regular attendance of the CF centre with at least 3 visits per
year. All subjects had complete medical records relative to the
2 years preceding the enrolment with clinical reports, height,
weight, BMI, pulmonary function tests, sputum cultures,
blood tests, specific aspergillum IgE titer, record of antibiotic
and steroid treatment. Perception of fitness and attitudes
towards physiotherapy were routinely checked and reported
in medical records by means of questionnaires. All patients
had received the prescription of physiotherapy with HiPEP.
3) At least one antibiotic treatment administered orally or
intravenously in the last 6 months for an acute respiratory
exacerbation, with a decrease of at least 10% FEV1 of their
best usual values.
Exclusion criteria were: less than 9 years of age, dyspnoea at
rest, recent clinically significant haemoptoe, need for additional
oxygen, cor pulmonale.
2.2. Trial design
Each subject enrolled served as his/her own control. All
patients who matched the inclusion criteria were consecutively
enrolled over a 2 year period, with 1 year of scheduled post
intervention follow-up. Upon enrolment, SpiroTiger was
offered instead of HiPEP. Data related to study outcomes
collected in the year before enrolment (data from clinical
records) were compared with data collected during the year of
follow-up. Post intervention measures were taken at least threeersonal training target values are entered into the basic unit and serve to monitor
such as “breathe faster” and a bar shows the respiration depth. The breathing
n from the ideal training frequency, the Spiro Tiger ® issues optical and acoustic
sic station where they are monitored and stored.
Table 2
Main characteristics of enrolled population (n=24)
Male sex n=24 (%) 58%
Age (mean, SD) 21.3 (6.6)
BMI (mean, SD) 20 (3.1)
Height (mean, SD) 165.2 (9.9)
Weight (mean, SD) 55.9 (13.2)
Colonized with n=24 (%):
Pseudomonas 17 (70.8)
Cepacia 5 (20.8)
MRSA 7 (29.2)
Serratia 1 (4.2)
Steroid treatment for aspergillosis n=24 (%) 2 (8.3)
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of 3 months from the end of the training. We decided to wait
3 months to obtain measures because there is evidence that the
placebo effect takes approximately 12 weeks to recede [12].
Patients were free to drop out from the study at any time and
go back to HiPEP or choose to have no physiotherapy. They
were also allowed to continue respiratory training for any length
of time they chose after the first year of follow-up.
Written informed consent was obtained before enrolment
from each patient or from the patient's legal guardian, when
younger than 18 years of age.
The Local ethical committee approved the study.
2.3. Training device
The SpiroTiger® training device consists of a hand-held unit
with a respiratory pouch and a base station (Fig. 1). The specific
properties of the device allow for personalized respiratory
training through maximal inspirations and expirations without
hypocarbia, and without the limitation of lower limbs muscles
involvement. To avoid hypocarbia despite hyperventilation the
Spiro Tiger® features a two way piston valve connecting to a
rebreathing bag. As the patient breathes out through the
mouthpiece, the rebreathing bag stores part of the expired air,
which contains increased concentrations of carbon dioxide.
Once the rebreathing bag is filled to its capacity, a valve opens
and allows the rest of the expired air to be released into the
environment. The valve shuts when expiration finishes and
inspiration starts. Inspiration empties the rebreathing bag first
(containing increased concentrations of carbon dioxide), then
the valve opens and some fresh outside air is inspired at the end
of each inspiration.
Personal training target values are entered into the base unit
and are used to monitor the breathing frequency and depth
during training.
The base station in the hand-held computer monitors the
breathing frequency, sets threshold limits for breathing patterns,
and displays visual and acoustic feedback so as to allow the
subject to breathe within the threshold values for isocapnia.
The base station also stores time and frequency of each
exercise session, thus allowing the patient and his/her health
care provider to retrieve and review the data.
2.4. Setting of training sessions and training parameters
Training parameters were established by the respiratory
physiotherapist, based on the patient's respiratory tests, clinicalTable 1
Patients’ perception of physical fitness
1. Choose three physical activities you like to do, and that represent your well
being status (e.g. Swimming, playing soccer, going for a walk)
2. Give a mark from 0 to 10 to each activity based on the difficulties you
experience in performing it. 10 is the best desirable result (no difficulty), 0 the
worst (I can't do it).
Example of the questionnaires used.conditions and on the results of a preliminary test on the training
machine. Rebreathing bag size and respiratory frequency are
crucial in ensuring end-expiratory CO2 concentrations within
acceptable physiological parameters. All sessions are dedicated
to a single clinically stable patient and performed in the CF clinic
by the physiotherapist who has been in charge of the treatment in
previous years. Four training sessions of 30 min each over a
3 month period were performed:
- First session: theory, explanations, demonstration, and
10 min training.
- Second session: breathing co-ordination and choice of the
rebreathing bag.
- Third session: targeting patients' outcomes in terms of
respiratory frequencies, volume of the pouch, feed-back levels.
- Fourth session: two minute warm-up at 26–27 breaths/min,
followed by a 14 min training at 29–30 breaths/min.
Training sessions are strictly tailored on patients’ respiratory
function. Patients with more severe respiratory conditions
were trained with lower frequencies to avoid the risk of
shortening expiratory time with hyperinflation.
• The choice of the rebreathing bag's volume was based on the
patient's forced vital capacity (FVC), starting with a
rebreathing bag size roughly equivalent to half the patient's
FVC.
• The respiratory rate was initially set at 24 breaths/min for
2 min, eventually using 2 min of maximal inspiratory and
expiratory breaths at an increasing breathing frequency.
• Frequency and length of training cycle: a daily training
session was performed for the first week at a frequency of
27–28 breaths/min for a period of 10 min then increased to at
least 14 min, at least 4 days a week.
• Intensifying the training: this was obtained by increasing the
rebreathing bag volume by 10% in the last 3–4 min in order to
increase the work load. Increasing the rebreathing bag volume
is preferable to increasing the respiratory frequency in patients
with important lung involvement who are at risk of delayed
emptying of alveolar units with lower constant of time.
2.5. Antibiotic treatment policy
Oral antibiotic treatment was prescribed for minor respiratory
exacerbations (increased cough, increased sputum expectoration,
Table 3
Main results (n=24)
Before After P
FVC % predicted (mean, SD) 93.2 (17.3) 98.5 (14.3) 0.003
FEV1 % predicted (mean, SD) 75.9 (20.5) 81.3 (24.4) 0.002
FEF 25–75 % predicted (mean, SD) 54.1 (33) 57.1 (37.8) 0.5
Oral antibiotics (cycles/year) (mean, SD) 2 (1.3) 1.96 (1.2) 0.8
Intravenous antibiotics (cycles/year)
(mean, SD)
1.8 (1.4) 1 (1.3) 0.001
Perception of physical fitness (mean, SD) 6.1 (1.2) 9.1 (0.8) b0.001
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FEV1 above 10%, increased CRP). Intravenous antibiotics were
prescribed for more important respiratory exacerbations, or in
the case of inadequate response to oral treatment. Inhaled anti-
biotic treatment was prescribed to maintain stable pulmonary
function in patientswhoweremore likely to have a faster decrease
in FEV1 and FVC, requiring frequent intravenous treatments.
This antibiotic treatment policy did not change over the study
period.
2.6. Measures of outcomes
Lung function (FVC, FEV1, FEF 25-75) wasmeasured at 3 to
4 months intervals in the year before and during treatment using
a dry wedge SensorMedics Vmax 22 spirometer (SensorMe-
dics®, Milano, Italy). For each lung function outcome data was
calculated as average value before and during treatment. All
parameters were expressed as percentage prediction according to
age, height and gender.
The number of antibiotics treatments was recorded before
and during the period of the study.
The perception of physical fitness was routinely measured by
means of an analogue scale at every control visit. Patients were
asked to specify three physical activities that could representFig. 2. Graphical representation of FEV1 values in patients wtheir physical fitness. Patients were then instructed to assign
a mark from 0 to 10 based on the difficulty to carry out physi-
cal activities due to dispnoea or other pulmonary symptoms
(0 being the worst value and 10 the best). For each patient we
calculated the average scores on a minimum of three controls
before and during treatment. An example of the questionnaires
is shown in Table 1.
Adherence to treatment was assessed using the software
included in the training device. Adherence to treatment was
arbitrarily defined as good for evidence of training 6 days out of
7 for at least 16 min, as low for evidence of training more than
3 days out of 7 for at least 16 min, and as absent (no adherence)
below 3 days a week.
Patients’ opinions on the amount of cough, on easiness
in mucus expectoration and on dyspnoea were investigated
by means of a questionnaire administered before the
beginning of the study and repeated after 6 months of
treatment. Patients were asked to assign a mark from 0 to 10
on a visual analogue scale, 0 being the worst value and 10
the best.
2.7. Statistical analysis
We did not perform an “a priori” sample size calculation due
to the characteristics of the study (pilot study). We also
estimated to enrol all subjects who matched the above reported
inclusion criteria in the study period. Furthermore, there were
no previous studies on SpiroTiger in CF patients.
Data presented in the results are referred to the whole year
before and after the enrolment. Categorical data are presented as
numbers and percentages, continuous variables as means and
standard deviations (SD). Differences between continuous
variables were evaluated using a non-parametric test for paired
data (Wilcoxon Signed Ranks Test), assuming a non-normal
distribution of data. The statistical analysis was carried out with
SPSS 11.0 statistical software.ith good compliance. Each number represents a patient.
Table 4
Patients' opinions (n=23)
hiPEP mask STM
(Spiro Tiger Medical)
P
Efficacy of treatment in
reducing the amount of
cough (mean, SD)
0.7 (0.5) 8.4 (1.4) b0.001
Efficacy of treatment in
mucus drainage
(mean, SD)
2.9 (1.7) 9.3 (0.8) b0.001
Efficacy of treatment in
reducing dyspnoea with
effort (mean, SD)
0 9.3 (0.6) b0.001
Results are expressed in terms of 0–10 on a visual analogue scale (0 is the worst
value, 10 is the best).
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3.1. Study group characteristics
SpiroTiger training was offered to 24 patients and all
accepted to enter the study. Demographic and clinical data are
shown in Table 2.
All patients started the initial training, 2 patients did not
regularly attended the first 4 scheduled training sessions;
none decided to stop training and returned the training
device or went back to HiPEP. All patient were followed up
for 1 year after enrolment. The data presented are referred to
the complete year before and after the enrolment. Lung
function tests, cycles of oral and intravenous antibiotics
treatments, perception of physical fitness before and after the
period of the study are all shown in Table 3. Graphical
representation of FEV1 over the study period is shown in
Figs. 2 and 3.
3.2. Inhaled antibiotic treatment
5 out of 24 patients received inhaled antibiotic during the
study period: 2 patients in the year before and during
intervention, 1 only in the year before intervention, and 1
started inhaled antibiotics treatment in the year of intervention.
1 patient who was assuming inhaled treatment in the year before
intervention stopped it while using Spiro Tiger®.
3.3. Adherence to treatment
15/24 patients (63%) showed good adherence to the
treatment with SpiroTiger; 7/24 (29%) low adherence; 2/24
(8%) no adherence.
Patients’ opinions: questionnaire results are shown in
Table 4. Data were available for 23/24 patient. One patientFig. 3. Graphical representation of FEV1 values in patients with low and no compl
represented in dotted lines.with insufficient adherence to treatment did not answer the
questionnaire.
4. Discussion
In this experience respiratory training through a specific
commercial device in CF patients was associated with improved
lung function and perception of physical fitness.
The study has some limitations, in particular the lack of a
measure of respiratory muscle strength, the design without a
control group, and the possible bias due to the increased
attendance in CF clinic required for the training. To limit these
possible biases we chose a long term follow-up, and strong
parameters of outcome such as respiratory function and
adherence to physiotherapy. We didn't measure quality of life
using a specific questionnaire (e.g. St. George Respiratory
Questionnaire or AQ20). According to the literature it is
difficult to administer standardised questionnaires to an
extremely variable population such as that of patients with CFiance. Each number represents a patient, the two patient with no adherence are
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perception of physical fitness.
In CF patients, the lung disease and the secondary chest
and muscle alterations are associated with a reduction in
compliance and elastic recoil, with an increase in respiratory
resistance and hyperinflation. With time, the loss of fat-free
mass in chest muscles further reduces inspiratory muscle
function. It has been demonstrated that the force that a skeletal
muscle can generate depends on its effective cross-sectional
area and on the geometry with which it applies its tensile force
[15]. For this reason the increase of the cross-sectional area
of the inspiratory muscles due to hypertrophy may reverse
or delay the consequences of impaired inspiratory muscle
function.
In our experience a specific respiratory training device led to
an increase in ventilation without hypocarbia, at the same time
allowing for feed-back during exercise, good focusing and
flexibility of the training, and control of adherence to treatment
through the software. No breathing resistances are used in this
device, while it allows for maximal inspirations and expirations
which are usually rarely experienced by CF patients who are
limited by scarce endurance of inferior limb muscles. The
hypothesis is that this kind of respiratory training, which is
made possible by the design of the device, produces an
advantageous stretching effect on chest wall.
Enright et al. [11] demonstrated that inspiratory muscle
training over an 8 week program improves lung function and
exercise capacity in adults. Keens et al. in 4 weeks of
normocapnic-hyperpnea and resistive breathing showed an
improvement of endurance and strength, but the effects were no
grater than those obtained by general aerobic exercise training
[16]. Asher et al. after 6 weeks with low-intensity inspiratory
threshold loading at 40% of maximal inspiratory pressure,
showed an improvement in inspiratory muscle endurance but no
effects on pulmonary function [17]. It has been demonstrated
that in CF patients, greater levels of aerobic fitness and exercise
capacity are associated with lower levels of mortality [18] and
improved psychosocial status [19] respectively. The hypothesis
is that the specific properties of the device provide respiratory
training and increase mucus clearance. To the best of our
knowledge, no previous studies have addressed both these
issues at the same time.
Since these activities involve building up muscle mass,
specific care to ensure adequate nutrition should be taken with
these patients [20].
Given the long follow-up and the expected decline in lung
function in time in CF patients [21,22], our positive results are
encouraging in terms of pulmonary tests, perception of physical
fitness and, to a lesser extent, reduced requirement for intrave-
nous antibiotic treatment.
Indeed, patients’ opinions showed a preference for respira-
tory training with this device with respect to HiPEP, with a
relevant subjective perception of benefit in several every day
life aspects. It is well known [23] that adherence to
physiotherapy is variable in CF patients, the percentage of
adult patients carrying out daily chest physiotherapy being
lower than 30%. Our series is limited to 24 patients and moredata are needed, but the percentage of patients maintaining good
adherence to the treatment argues in favour of the perception of
benefit and efficacy of this approach.
In conclusion this study shows an association between
respiratory training through a specific commercial device and
improved lung function. Further well designed trials are needed
to confirm this preliminary report.
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